WATCHLONGEVITY

Sunday, June 21, 2026

STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drug
DEVELOPING
Importance
62
Trust
71
Urgency
65
CLINICAL TRIAL

STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drug

Boehringer Ingelheim released Phase 3 trial results for survodutide, its obesity drug. The drug cut liver fat well but didn't reduce weight as much as some competitors, raising questions about how it will compete in the market.

Analysis

Survodutide's Phase 3 weight loss looks weaker than rivals. That may make it harder to sell against Ozempic and Zepbound when it reaches market.

  • Survodutide Phase 3 data showed strong liver fat reduction
  • Weight loss results appeared lower than some competing obesity drugs
  • Data described as potentially hurting survodutide's competitive position
$ZLDPF
survodutideBoehringer Ingelheim
STAT News — Pharma13d
Read
BREAKING
Importance
82
Trust
71
Urgency
95
CLINICAL TRIAL

Boehringer’s GLP-1 dual agonist survodutide shines in phase III trial - European Pharmaceutical Review

Boehringer's survodutide, a GLP-1 drug that works two ways to help control weight and blood sugar, passed a major late-stage trial (Phase 3). The results show the drug works well and may move toward approval.

Analysis

Survodutide hit its goal in a late-stage trial. That gives Boehringer and Zealand a real shot at the obesity market now ruled by Lilly and Novo.

  • Boehringer's survodutide passed a Phase 3 trial
  • Survodutide is a dual GLP-1 agonist for weight and blood sugar
  • Trial results may support a path to approval
$ZLDPF$LLY$NVO
survodutideBoehringer Ingelheim
Retatrutide News1mo
Read
BREAKING
Importance
78
Trust
71
Urgency
95
CLINICAL TRIAL

Dual-Agonist Survodutide Shows Significant Weight Loss in Phase III Obesity Trial - BioPharm International

Survodutide, a dual-action weight-loss drug, showed strong results in a large Phase 3 trial for obesity. The drug is one of several new peptide medications being tested to compete with Ozempic and Mounjaro.

Analysis

Survodutide is the next weight-loss shot lining up to take on Ozempic and Mounjaro. Strong Phase 3 results give Zealand and Boehringer a real shot at the market.

  • Survodutide is a dual-action peptide drug for obesity.
  • Phase 3 obesity trial showed significant weight loss.
  • Aimed at competing with Ozempic and Mounjaro.
$ZLDPF
survodutide
Retatrutide News1mo
Read
BREAKING
Importance
88
Trust
80
Urgency
95
CLINICAL TRIAL✓ 5 outlets

Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial - BioSpace

Boehringer Ingelheim's survodutide, a dual-action weight-loss drug, helped people lose 16.6% of their body weight in a Phase 3 trial (a large final test before approval). The drug also improved other health markers related to weight and metabolism.

Analysis

Survodutide helped patients lose 16.6% of their weight. That puts Boehringer and Zealand in the same league as Wegovy and Zepbound for obesity care.

  • Survodutide hit 16.6% weight loss in a Phase 3 trial
  • Drug is a glucagon/GLP-1 dual agonist from Boehringer Ingelheim
  • Trial enrolled people with obesity or overweight
$ZLDPF$LLY$NVO
survodutideZealand PharmaBoehringer Ingelheim
BioSpace1mo
Read